Clinical use of TIMP-2•IGFBP7 biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel

摘要

BackgroundThe first FDA-approved test to assess risk for acute kidney injury (AKI), [TIMP-2]•[IGFBP7], is clinically available in many parts of the world, including the USA and Europe. We sought to understand how the test is currently being used clinically.